methods:In 7 serial coronary intravascular ultrasound trials, 3469 statin-treated patients with coronary disease were stratified according to achieved LDL-C (< or ≥70 mg/dL) and changes in HDL-C (≥ vs. < median) (Table) . Changes in coronary percent atheroma volume (PAV) and MACE (cardiovascular death, non-fatal MI, stroke, coronary revascularization, hospitalization for unstable angina) were evaluated across these groups.
results: Overall, the median change in HDL-C was +6.03%, and the mean LDL-C across the LDL-C stratified groups was 55.2±11 and 97.4±22 mg/dL. In patients with achieved LDL-C <70 mg/dL, greater HDL raising did not associate with disease regression [OR 1.10 (95% CI 0.86, 1.42), p=0.44] or lower MACE [HR 1.26 (95% CI 0.93, 1.49), p=0.11]. In those with achieved LDL-C ≥70 mg/dL, greater HDL raising was associated with less disease progression [OR 0.76 (95% CI 0.52, 0.96), p=0.018] and lower MACE [HR 0.75 (95% CI 0.47, 0.98), p=0.032] (Table) .
conclusions: During statin therapy, raising HDL-C appears beneficial in patients with achieved LDL-C levels ≥70 mg/dL, but not with levels <70 mg/dL. These findings outline the need for additional therapeutic strategies for reducing residual risk in those with LDL-C <70 mg/dL. 
